Universal Vision Biotechnology Co

Universal Vision Biotechnology Co Enterprise Value

The Enterprise Value (EV) of Universal Vision Biotechnology Co (3218.TWO) as of Oct 31, 2026 is 11.48 B TWD. In the previous year, Enterprise Value (EV) was 12.53 B TWD — a change of -8.41% (lower).

Enterprise Value

11.48 BTWD

YoY

-8.41%

Last updated:

Enterprise Value (EV) of Universal Vision Biotechnology Co is 2025 11.48 B TWD. Enterprise Value (EV) of Universal Vision Biotechnology Co was 2024 12.53 B TWD. It decreases by -8.41% lower compared to the previous year.

The Universal Vision Biotechnology Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
11.63 B TWD
Jan 1, 2019
11.35 B TWD
Jan 1, 2020
11.02 B TWD
Jan 1, 2021
11.21 B TWD
Jan 1, 2022
10.98 B TWD
Jan 1, 2023
10.62 B TWD
Jan 1, 2024
12.53 B TWD
Jan 1, 2025
11.48 B TWD
The Universal Vision Biotechnology Co Enterprise Value history
YEAREnterprise ValueYoY
11.48 BTWD-8.41%
12.53 BTWD+18.05%
10.62 BTWD-3.34%
10.98 BTWD-1.99%
11.21 BTWD+1.74%
11.02 BTWD-2.95%
11.35 BTWD-2.42%
11.63 BTWD+0.46%
11.58 BTWD-1.19%
11.72 BTWD-0.58%
11.79 BTWD-0.54%
11.85 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Universal Vision Biotechnology Co Stock analysis

What does Universal Vision Biotechnology Co do? Universal Vision Biotechnology Co., Ltd. generates revenue through the sale of optical instruments, glasses, contact lenses, and glass ornaments. The company also provides laser vision correction equipment and services, trades medical drugs, and offers leasing of medical facilities, clinic operation planning, and medical cosmetology services. Its primary market is Taiwan, where it serves customers seeking vision correction solutions and medical aesthetic treatments. The firm's product portfolio includes optical instruments, glasses, contact lenses, and glass ornaments, alongside medical drug trading. Services such as laser vision correction, medical facility leasing, clinic operation planning, and medical cosmetology are key revenue drivers. Taiwan-based customers, including individuals requiring vision care and clinics needing operational support, form the core market segment. Revenue streams are derived from the direct sale of optical products, medical drug trading, and service-based offerings like laser vision correction and medical cosmetology. The company operates exclusively within Taiwan, focusing on both consumer and clinic-level clients for its comprehensive vision and medical aesthetics solutions. Universal Vision Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Universal Vision Biotechnology Co stock

Enterprise Value (EV) of Universal Vision Biotechnology Co is 11.48 B TWD in 2025.

Enterprise Value (EV) of Universal Vision Biotechnology Co changed from 12.53 B TWD to 11.48 B TWD, representing a -8.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Universal Vision Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s TWD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' TWD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Universal Vision Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Universal Vision Biotechnology Co

All Key Metrics — Universal Vision Biotechnology Co